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Aims. Prognostic thresholds to identify new type 2 diabetes mellitus (T2DM) cases using the HOMA-IR have not been deﬁned. We
studied the HOMA-IR performance to identify incident T2DM cases and to assess if the thresholds varied according to urbanization
and altitude in Peru.Methods. Longitudinal analysis. The outcome was incident T2DM cases: self-report diagnosis and fasting glucose.
The exposure was the HOMA-IR. Receiver operating characteristic (ROC) curves were plotted, and the area under the ROC curve
(AUC) was estimated with 95% conﬁdence intervals (95% CIs). Results are presented overall and stratiﬁed by study site (Lima,
Tumbes, urban Puno, and rural Puno), rurality (urban, semiurban, and rural), and altitude (low and high). Results. A total of 3120
participants (mean age: 55.6 years, 51.2% females) contributed data to this analysis. The median baseline HOMA-IR was 1.7 (IQR
1.0–2.9), with median values ranging from 1.1 in rural Puno to 2.0 in Lima and Tumbes (p < 0 001). Overall for incident T2DM,
the AUC was 0.69 (95% CI: 0.64–0.74) with an empirical threshold of 2.8 yielding a positive likelihood ratio of 2.30 and a negative
one of 0.61; the positive and negative predictive values were 14.6% and 95.7%, respectively. The empirical thresholds varied within
the variables of interest, for example, from 0.9 in urban Puno to 2.9 in Lima. Conclusions. Using the HOMA-IR to identify incident
T2DM cases seems to yield moderate accuracy. The HOMA-IR could help improve identifying people at high risk of T2DM.
1. Introduction
Type 2 diabetes mellitus (T2DM) has become one of the larg-
est health problems in the world. It is among the top causes of
disability-adjusted life years as well as years lived with
disability, particularly in middle- and high-income countries
[1, 2]. The scenario is not diﬀerent in Peru, where
population-based studies in several areas reported a 7% prev-
alence [3, 4] and an incidence of two new cases per one
hundred person-years [4, 5]. These international and
national ﬁgures pinpoint the value of T2DM prevention
and early diagnosis.
An important approach to prevent or delay the T2DM
burden is to identify those individuals at high risk of
T2DM. Therefore, tools to identify T2DM cases, taking
advantage of available resources and which are reliable in a
target population, are needed. Laboratory facilities, along
with their processes and logistics, are known by health
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systems in low- and middle-income countries, even though
they may not be available in all health facilities. Identifying
laboratory-based tests for early identiﬁcation of T2DM may
be an important asset and can potentiate the use of available
resources instead of introducing completely new approaches.
In this line, the homeostasis model assessment for insulin
resistance (HOMA-IR), which combines fasting glucose
and insulin, could be an option [6–10]. The HOMA-IR
assesses the function of β-cells and thus informs physiologi-
cal changes that occur before the onset of T2DM (i.e., precur-
sor of T2DM) [11, 12], which makes this test a potential tool
to identify people at high risk of developing T2DM in the
near future. In addition, HOMA-IR thresholds to identify
T2DM cases have not been established, and neither have they
been studied in populations living in places at diﬀerent stages
of urbanization or altitude above the sea level. Consequently,
this study is aimed at determining the HOMA-IR perfor-
mance to identify incident T2DM cases in four areas in Peru.
This study is aimed at providing evidence to further use exist-
ing laboratory tests—insulin and glucose—that could be
available in health facilities.
2. Methods
2.1. Study Design. This is a longitudinal analysis using data of
the CRONICAS Cohort Study [13]. Brieﬂy, the CRONICAS
Cohort Study is a population-based prospective cohort which
started in September 2010. To date, two follow-up rounds
have been conducted, ﬁfteen and thirty months, on average,
after the baseline recruitment.
2.2. Study Scenario. The CRONICAS Cohort Study was con-
ducted in four Peruvian areas: Lima, Tumbes, rural Puno,
and urban Puno [13]. These sites have diﬀerent socioeco-
nomic and geographical features. Lima is a highly urbanized
metropolis at sea level. Tumbes is a semiurban area at sea
level. Puno is a city at 3825 meters above the sea level, from
which two diﬀerent sites—urban and rural—were studied.
National statistics rank Lima with the highest human
development index (0.63), followed by Tumbes (0.52) and
then Puno (0.39) [14]. The 62.6% of the population in Lima
had any health insurance, and this ﬁgure for Tumbes and
Puno was 68.7% and 60.7%, respectively [15]. The illiteracy
frequency for people aged ≥15 years in these settings was
2.3% in Lima, 3.0% in Tumbes, and 9.4% in Puno [16],
whereas life expectancy was 77 years in Lima, 74 years in
Tumbes, and 70 years in Puno [17].
2.3. Study Population. At baseline, the CRONICAS Cohort
Study aimed for a sex- and age- (35–44, 45–54, 55–64, and
≥65 years) stratiﬁed random sample of at least 1000 people
in each study setting (500 in urban and rural Puno) [13].
An updated census was used to identify eligible subjects at
each site. Accounting for all study locations, 11,544 people
were identiﬁed, 4325 were enrolled, and 3741 were surveyed.
At baseline, 3601 people were available with complete ques-
tionnaires. Regarding the follow-up rounds, 2892 (80.3%)
individuals were recontacted in the ﬁrst follow-up, while in
the second follow-up, this number was 2726 (75.7%) people.
Because this work focused on incident diabetes, prevalent
cases were excluded.
3. Variables
3.1. Outcome Variables. The outcome of interest was incident
T2DM. T2DM new cases were identiﬁed at the second
follow-up because of data availability. Having excluded
T2DM cases at baseline (self-reported T2DM diagnosis made
by a physician, currently taking medication for diabetes, and
a fasting plasma glucose≥ 126mg/dl), incident cases were
identiﬁed if they were receiving medication for T2DM or
had a fasting plasma glucose≥ 126mg/dl. Blood samples
were collected by a trained technician. Venous blood was
withdrawn after a fasting period of eight to twelve hours.
Plasma glucose was measured with an enzymatic colorimet-
ric technique (GOD-PAP; modular P-E/Roche-cobas, Gren-
zach-Wyhlen, Germany) [13].
3.2. Exposure Variable. The exposure of interest was the
HOMA-IR measured at baseline. This variable was com-
puted as glucose (mmol/l) times insulin (μU/ml), all divided
by 22.5 [(glucose∗insulin)/22.5] [18]. Blood samples for
insulin were retrieved following the same procedures as
explained above. Serum insulin was assessed using electro-
chemiluminescence (modular P-E/Roche-cobas) [13].
3.3. Other Variables.Other variables were assessed at baseline
following standard questionnaires [13]: sex (men and
women); age (35–44, 45–54, 55–64, and ≥65 years); educa-
tion (<7, 7–11, and ≥12 years of education); study site (Lima,
Tumbes, urban Puno, and rural Puno); altitude above the sea
level (low altitude included Lima and Tumbes and high alti-
tude encompassed Puno); rurality (urban for Lima as well as
urban Puno, semiurban for Tumbes, and rural for rural
Puno); and asset index, which is a numerical indicator based
on household assets (in tertiles). Weight (kg), height (cm),
and waist circumference (cm) were measured with calibrated
devices with the participants wearing light clothes and
shoeless [13]. Hemoglobin A1C (HbA1c) was assessed with
high-performance liquid chromatography (D10, Bio-Rad,
Munich, Germany) [13]. For descriptive purposes, the
HOMA-B was also estimated: (20× insulin)/(glucose− 3.5)
[18]. Follow-up time was estimated as the time diﬀerence
between baseline and follow-up, except for people who devel-
oped T2DM whose follow-up time was deemed to be half of
the observed follow-up time diﬀerence. This is a conservative
approach taking into consideration that T2DM could have
appeared anytime between assessments.
4. Statistical Analysis
The analyses were conducted with STATA v13.0 (StataCorp,
College Station, TX, USA). For descriptive purposes,
numerical variables were summarized with means along
with standard deviations or medians with the corresponding
interquartile range (IQR). Categorical variables were summa-
rized using proportions. To compare numeric variables
according to other categorical variables, the Wilcoxon rank-
sum and the Kruskal-Wallis rank tests were used. For
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comparison of categorical variables, the chi-squared test was
conducted. To estimate the p value for trend, the Cuzick test
(nptrend command) was used. The receiver operating charac-
teristic (ROC) curve was plotted, and the area under the ROC
curve (AUC) was estimated using the roctab command. The
AUC was compared among study sites, as well as by altitude
and rurality using the roccomp command. Finally, empirical
thresholds for the HOMA-IR to identify incident T2DM case
were estimated with the cutpt command and the youden
option; these calculations yielded the Youden’s index, sensi-
tivity, speciﬁcity, and the AUC for each given threshold. To
estimate the 95% conﬁdence interval (95% CI) of each empir-
ical threshold and its corresponding AUC, a postestimation
bootstrap technique was followed assuming one thousand
replications without replacement. The positive likelihood
ratio was estimated as sensitivity over one minus speciﬁcity,
whereas the negative likelihood ratio was deﬁned as one
minus sensitivity over speciﬁcity. The negative predictive
value was estimated as [sensitivity×prevalence] divided by
[sensitivity×prevalence + (1− speciﬁcity)× (1−prevalence)];
the negative predictive value was computed as [speciﬁc-
ity× (1−prevalence)] divided by [(1− sensitivity)×preva-
lence + speciﬁcity× (1−prevalence)]. In order to assess
whether the expected (using the HOMA-IR as predictor)
and observed number of diabetes cases matched across all
doses of the exposure (the HOMA-IR divided in deciles),
we used the Hosmer-Lemeshow chi-squared goodness of ﬁt
test; high p values (p > 0 05) mean that the expected and
observed numbers of cases are similar; thus, the predictor
shows good calibration. To compare the AUC yielded for
incident T2DM between the HOMA-IR and HbA1c, the roc-
comp command was used; this tests if the AUC is equal
between assessment methods.
5. Ethics
The protocol of the CRONICAS Cohort Study was reviewed
and approved by three independent Institutional Review
Boards in Peru and in the USA: Universidad Peruana Caye-
tano Heredia and Associaion Beneﬁca PRISMA in Lima,
Peru, as well as by the Johns Hopkins University in Balti-
more, USA. All participants gave verbal informed consent
[13]. The research was conducted in accordance with the
Helsinki declaration.
6. Results
6.1. Study Population at Baseline. There were 3601 subjects,
though 481 (13.4%) were excluded because of missing
values in baseline glucose or insulin; there were no diﬀer-
ences in gender and age, but excluded subjects were
poorer and there were more excluded subjects in Puno
(Supplementary Table 1).
At baseline, mean age was 55.6 (SD: 12.7) years, and
51.2% of the study sample was female. The prevalence of
T2DM was 6.9% (95% CI: 6.1%–7.9%). The median
HOMA-IR was 1.7 (IQR 1.0–2.9) and the median HOMA-
B was 96.4 (IQR 59.5–149.7). Further details about these
sociodemographic and clinical variables are shown in
Table 1, overall and by study site.
6.2. HOMA-IR: Characteristics at Baseline. Diﬀerences in the
HOMA-IR by sociodemographic and clinical variables are
shown in Table 2. Median values of the HOMA-IR varied
among urban, semiurban, and rural sites: 1.8, 2.0, and 1.1
(p for trend< 0.001), respectively. The higher the wealth
index, the higher the HOMA-IR: median of 1.4 at the bottom
tertile and of 2.0 at the top tertile (p for trend< 0.001).
6.3. New Diabetes Cases. The mean follow-up time was 2.3
(SD: 0.5) years. Among those who did not have T2DM at
baseline, 120 people developed T2DM. Subjects who devel-
oped T2DM at follow-up had higher HOMA-IR at baseline
in comparison to those who did not develop T2DM
(p < 0 001): the median was 2.9 (IQR: 1.7–4.3) and 1.7
(IQR: 1.0–2.7), respectively. A similar diﬀerence was
retrieved when comparing these populations regarding fast-
ing glucose at baseline (p < 0 001): subjects who did not
develop T2DM had a median glucose of 91.0mg/dl (IQR:
85.0–97.9) and those who developed T2DM had a median
glucose of 102.5mg/dl (IQR: 91.7–116.0).
6.4. HOMA-IR: Diagnostic Performance for Incident Cases.
The AUC for incident T2DM cases was 0.68 (95% CI: 0.64–
0.74, Figure 1). The AUC for each study population is pre-
sented in Table 3, along with the corresponding empirical
thresholds.
Empirical HOMA-IR thresholds were diﬀerent among
study sites, varying from 0.9 (95% CI: 0.00–1.96) to 2.9
(95% CI: 2.11–3.69) in urban Puno and Lima, respectively.
Dissimilar thresholds were also found according to altitude:
2.8 (95% CI: 2.20–3.48) at low and 1.2 (95% CI: 0.62–1.71)
at high altitude, as well as according to rurality: 2.5 (95%
CI: 1.67–3.26) in urban, 2.8 (95% CI: 1.80–3.88) in semiur-
ban, and 1.2 (95% CI: 0.76–1.58) in rural areas. There was
evidence of moderate calibration (p = 0 065), with good
agreement (Figure 2) in the tenth decile (i.e., highest
HOMA-IR level).
6.5. HOMA-IR in Comparison to HbA1c. The AUCwas larger
for HbA1c to predict new T2DM cases: 0.75 (95% CI: 0.70–
0.80, p = 0 023) for HbA1c.
7. Discussion
7.1. Main Results. In a population-based study conducted in
four Peruvian areas at diﬀerent stages of urbanization as well
as with diﬀerent sociodemographic and health proﬁles, the
HOMA-IR had moderate prediction accuracy for incident
T2DM cases in terms of discrimination and calibration.
The HOMA-IR thresholds for incident T2DM cases varied
according to study site, altitude, and degree of urbanization.
The HOMA-IR AUC was smaller in comparison to HbA1c,
suggesting that the latter could be preferred to identify people
at high risk of T2DM.
7.2. Comparison with Other Studies. Our AUC for incident
T2DM was moderate, which could signal that these people
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are still on their way to T2DM, i.e., would develop T2DM in
more than 2.3 years of follow-up. Another study with a
median follow-up of nine years and using oral glucose toler-
ance test (OGTT) as the gold standard reported an AUC of
72% for women and 66% for men [7]. Although prospective
evidence on the prediction accuracy of the HOMA-IR is still
scarce and deserves further comprehensive scrutiny across
populations and health backgrounds, the HOMA-IR appears
to have a moderate performance to identify incident T2DM
cases even after several years.
7.3. Result Interpretation. Including all the study population,
the threshold for incident T2DM cases was 2.8. Other
authors have suggested cutoﬀs of around 2.2 [7] and 2.0
[10]. These diﬀerences could be because of other determi-
nants of insulin resistance, e.g., visceral fat, or because those
populations have diﬀerent T2DM proﬁles or are at an
advanced stage of the nutritional transition. This would
mean that populations with higher levels of these risk factors
would experience detrimental eﬀects at lower thresholds of
insulin resistance [7]. Nevertheless, the distribution of body
mass index and waist circumference was comparable among
our study population and previous reports, suggesting that
other variables would explain these diﬀerences, perhaps
genetics or other unmeasured anthropometric features, such
as skinfolds [7, 10, 19].
According to study site, the 95% CIs of some empirical
thresholds overlap, especially the ones from sites in Puno
and those of Lima and Tumbes. However, the results do
not support using one threshold across all sites. Furthermore,
the positive and negative likelihood ratios are also more sim-
ilar between Lima and Tumbes and between Puno sites.
These pairwise similarities could be explained by shared
health proﬁles [4, 20]. This pattern across study sites is also
reﬂected in the empirical thresholds and their 95% CIs
according to rurality level: urban and semiurban sites showed
Table 1: Sociodemographic and clinical characteristics of study participants at baseline and overall and according to study site.
Variable Overall Lima Urban Puno Rural Puno Tumbes p value
Sex N = 3118 N = 1031 N = 517 N = 539 N = 1031 0.882
Female 51.2 51.8 50.9 52.1 50.3
Male 48.8 48.2 49.1 47.9 49.7
Age (years) N = 3118 N = 1031 N = 517 N = 539 N = 1031 0.934
35–44 24.3 24.0 24.8 22.8 25.3
45–54 25.5 27.1 25.0 25.4 24.4
55–64 25.4 25.2 25.7 25.4 25.3
65+ 24.8 23.8 24.6 26.4 25.0
Wealth index N = 3120 N = 1031 N = 517 N = 541 N = 1031 <0.001
Bottom 31.6 12.0 23.2 71.5 34.5
Middle 33.9 37.0 26.1 26.1 39.0
Top 34.4 51.0 50.7 2.4 26.5
Education N = 3118 N = 1030 N = 517 N = 541 N = 1030 <0.001
<7 years 45.9 42.8 14.7 62.9 55.6
7–11 years 32.9 39.7 27.3 30.5 30.3
≥12 years 21.2 17.5 58.0 6.7 14.1
Waist circumference N = 3115 N = 1031 N = 514 N = 540 N = 1030 <0.001
Mean (SD) 91.9 (11.0) 92.4 (10.5) 92.6 (10.8) 85.0 (11.0) 94.6 (10.2)
Body mass index N = 3116 N = 1031 N = 514 N = 540 N = 1031 <0.001
Mean (SD) 27.7 (4.6) 28.4 (4.6) 27.8 (4.3) 25.1 (3.7) 28.3 (4.8)
HbA1c N = 3119 N = 1031 N = 516 N = 541 N = 1031
Median (IQR) 5.8 (5.5–6.1) 5.7 (5.4–5.9) 5.9 (5.6–6.1) 5.8 (5.6–6.1) 5.9 (5.6–6.2) <0.001∗
Diabetes N = 3120 N = 1031 N = 517 N = 541 N = 1031 <0.001
Yes 6.9 5.5 7.0 3.1 10.3
HOMA-B N = 3118 N = 1030 N = 517 N = 540 N = 1031 <0.001∗
Median (IQR) 96.4 (59.5–149.7) 108.0 (68.8–162.8) 95.5 (60.9–153.2) 74.1 (46.1–119.2) 98.6 (57.9–149.2)
HOMA-IR N = 3120 N = 1031 N = 517 N = 541 N = 1031
Median (IQR) 1.7 (1.04–2.94) 2.0 (1.17–3.19) 1.6 (1.04–2.75) 1.1 (0.62–1.76) 2.0 (1.23–3.42) <0.001∗
Results are presented as percentages for categorical variables. p values for categorical variables refer to the chi-squared test among study sites, whereas for
numerical variables (waist circumference and body mass index) to the analysis of variance. ∗p value refers to the Kruskal-Wallis equality-of-populations
rank test among study sites.
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95% CIs that closely overlap, whereas rural sites have diﬀer-
ent ranges. The evidence when looking at altitude above the
sea level appears to be more conclusive and suggests that
Puno (i.e., high-altitude sites) needs a diﬀerent threshold
than Lima and Tumbes.
Across sites and empirical thresholds, the negative pre-
dictive values were above 95%, suggesting that this test could
be used to “rule out” future cases or at least to signal people
that could have a less thorough follow-up with other diabetes
biomarkers in the near future. Even though all positive likeli-
hood ratio estimates were small and would not suppose a
large change in the pretest probability, the largest estimate
was found in Tumbes. This could highlight the unhealthy
proﬁle of this population [4, 20], thus the already high prob-
ability of ﬁnding diabetes cases among them. On the other
hand, and consistent with the high negative predictive values,
there were relevant negative likelihood ratio estimates in
Puno. In other words, and consistent with an overall health-
ier proﬁle of this population, someone with a negative test
result would have low probabilities of becoming diabetic in
the near future.
7.4. Public Health Relevance. Current diabetes guidelines rec-
ommend screening for all people above 45 years of age or if
they have risk factors for diabetes and to repeat the screening
within the next three years, though this could be shorter
depending on initial results [21]. Our ﬁndings could support
testing a person with a negative HOMA-IR result in more
than a year, but less than 2.3 years (follow-up period). Our
results indicated large negative likelihood ratio and negative
predictive value estimates across sites. These metrics suggest
that it is unlikely for a person with a negative result to
develop T2DM in the next 2.3 years, albeit this evidence
should be interpreted in light with the study limitations and
according to each patient’s characteristics as well as the
epidemiological proﬁle of the population. Future studies
should verify our results and test their implementation in
clinical practice.
Current massive testing with the HOMA-IR could be
limited by economic shortcuts, which in turn reﬂects a
slightly less easy laboratory process. In a Peruvian public hos-
pital, a fasting glucose, an OGTT, and an insulin test cost 1.0
US$, 2.8 US$, and 3.4 US$, respectively [22]. In a thirty-
month period, a given subject could have three fasting glu-
cose tests, totaling 3.0 US$. If, however, this subject were
tested with the HOMA-IR (4.4 US$), he could have under-
gone one test only in the same period. This may not be
cost-eﬀective (3.0 US$ vs. 4.4 US$), also when compared to
HbA1c, which yielded better AUC in our results. Neverthe-
less, the HOMA-IR could be useful in rural areas where lab-
oratories are not available and thus people have additional
expenses (e.g., time and transportation) to get screening;
thereby, people from rural areas could commute (although
this consumes additional time and costs), have a HOMA-IR
test, and should it be a negative result, then follow-up
Table 2: The baseline HOMA-IR according to sociodemographic
variables.
Variable Median (IQR) p value
Sex <0.001
Female 2.0 (1.2–3.4)
Male 1.5 (0.9–2.5)
Age (years) <0.001/<0.001
35–44 1.8 (1.1–2.9)
45–54 1.8 (1.1–3.1)
55–64 1.9 (1.2–3.3)
65+ 1.5 (0.8–2.6)
Asset index <0.001/<0.001
Bottom 1.4 (0.8–2.4)
Middle 1.8 (1.1–3.0)
Top 2.0 (1.3–3.4)
Education <0.001/<0.001
<7 years 1.7 (1.0–2.9)
7–11 years 1.7 (1.0–2.9)
≥12 years 2.0 (1.2–3.1)
Study site <0.001
Lima 2.0 (1.2–3.2)
Urban Puno 1.6 (1.0–2.8)
Rural Puno 1.1 (0.6–1.8)
Tumbes 2.0 (1.2–3.4)
Altitude <0.001/<0.001
Low 2.0 (1.2–3.4)
High 1.3 (0.8–2.2)
Rurality <0.001/<0.001
Urban 1.8 (1.1–3.0)
Semiurban 2.0 (1.2–3.4)
Rural 1.1 (0.6–1.8)
Diabetes <0.001
No 1.6 (1.0–2.7)
Yes 4.8 (2.6–8.5)
Results are presented as median (IQR). p values refer to the Wilcoxon rank-
sum or to the Kruskal-Wallis tests for independence; if there is a second
p value, it corresponds to the p value for trend.
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Figure 1: ROC for the HOMA-IR and incident diabetes cases at
follow-up.
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evaluations could be delayed one or two years, yet no further
than 2.3 years. Our result yielded strong negative predictive
values, suggesting that a person with a negative result has
low chances of developing T2DM; hence, follow-up visits
could be less often than on a yearly basis, as long as the over-
all health proﬁle allows. These are speculative arguments, and
the HOMA-IR requires further studies before its enactment
is strongly suggested or discouraged.
Other blood-based test is HbA1c, which, in comparison
to the HOMA-IR, appears to be more accurate, cheaper,
and less cumbersome because it does not require a fasting
period. Notwithstanding, HbA1c needs high-quality process-
ing to secure consistent results and could also have some lim-
itations at high altitude [23]. Other studies have assessed
HbA1c to predict T2DM cases. In China, for example, the
AUC was 64.5% (medial follow-up: 4.6) [24], while in rural
Korea, it was 74% (median follow-up: 4.0 years) [25]. Our
AUC for HbA1c (and AUC) for incident T2DM cases was
in between these ﬁgures.
On the other hand, the overall results at the proposed
threshold signal a higher speciﬁcity than sensitivity. This
means that it would be more likely to identify healthy people
(i.e., without risk of developing T2DM). This has public
health relevance because knowing who is not likely to
develop T2DM would allow allocating (limited) resources
to high-risk individuals. Furthermore, the ratio between true
positive and false negative, as derived from the overall sensi-
tivity and speciﬁcity estimates, is 1.13. This reveals that for
each 10 false negatives, roughly 11 true positive cases would
be identiﬁed.
7.5. Strengths and Limitations. This study beneﬁts from a
relatively large sample size, but most importantly from
including participants from study sites with diﬀerent socio-
demographic and health characteristics. We analyzed pro-
spective data, which allowed us to study the short-term
eﬀect of the HOMA-IR to identify new T2DM cases. Never-
theless, limitations of the study need to be acknowledged too.
First, our T2DM diagnosis was based on fasting glucose. If in
addition to or in replace of this method we have used another
one, namely, OGTT, we could have detected more T2DM
cases. However, if this were the case, our results are still con-
servative and there could have been a larger AUC. Second,
most of the subjects excluded from the analysis were from
Puno. Results for this site should thus be interpreted cau-
tiously. Third, some subjects were lost to follow-up; thus,
there could have been more new cases. Our results warrant
further veriﬁcation, i.e., external validation. Fourth, although
diﬀerences across sites could be attributed to diﬀerent labora-
tory methods, all samples were analyzed by the same labora-
tory minimizing this potential bias.
8. Conclusions
Using the HOMA-IR to identify incident T2DM cases seems
to yield moderate accuracy. Given the increasing burden of
T2DM, actions need to be taken to improve the early identi-
ﬁcation of these patients. Using available laboratory facilities
to assess the HOMA-IR could have positive results.
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